Bolt Biotherapeutics (BOLT) has priced its upsized initial public offering of 11.5M common shares at $20/share.

Bolt biootherapeutics (Bolt)将其1150万股的首次公开募股定价为20美元/股。

The company previously filed to offer 8.8M shares at a range of $16-$18 and then raised the offering to 10.5M shares for $18-$19 per share.

该公司此前申请发行880万股股票，发行价在16至18美元之间，随后将发行价提高至1050万股，每股发行价为18至19美元。

Underwriters' over-allotment is an additional 1.725M shares.

承销商超额配售了172.5万股。

The shares are expected to begin trading today on Nasdaq.

预计该公司股票将于今日在纳斯达克(Nasdaq)开始交易。

The company's pipeline contains lead candidate BDC-1001, a HER2 Boltbody Immune-Stimulating Antibody Conjugate. In preclinical safety studies, BDC-1001 was well tolerated and no adverse safety signals were observed. BDC-1001 is currently in a Phase 1/2 trial for the treatment of patients with HER2-expressing solid tumors, and the company expects to move into Phase 2 dose expansions in key solid tumor indications with unmet medical need in 2021.

该公司的管道包括lead候选BDC-1001，一种HER2螺栓体免疫刺激抗体结合物。在临床前安全性研究中，BDC-1001的耐受性很好，没有观察到不良的安全信号。BDC-1001目前正在进行1/2期临床试验，用于治疗her2表达实体肿瘤患者，公司预计将在2021年对未满足医疗需求的关键实体肿瘤适应症进行2期剂量扩展。

Company's drug development pipeline:

公司的药物开发管线:

The company's major competitors are : AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN), AstraZeneca (NASDAQ:AZN), Bristol-Myers Squibb (NYSE:BMY), Eli Lilly (NYSE:LLY), Genentech, GlaxoSmithKline (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Novartis (NYSE:NVS), Pfizer (NYSE:PFE), Roche (OTCQX:RHHBY) and Sanofi (NASDAQ:SNY).

该公司的主要竞争对手是:艾伯维、安进、阿斯利康、百时美施贵宝、礼来、基因泰克、葛兰素史克、强生、默克、诺华、辉瑞、罗氏和赛诺菲。